Evidence map›Paper›PMID 32646245›Full record

ArticleJournal of investigative medicine high impact case reports

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.

Stefania Federica De Mercanti, Dario Gned, Manuela Matta, Marco Iudicello, Emanuele Franchin, Marinella Clerico

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Stefania Federica De MercantiUniversity of Torino, Orbassano, Italy.
Dario GnedSan Luigi Gonzaga Hospital, Orbassano, Italy.
Manuela MattaUniversity of Torino, Orbassano, Italy.
Marco IudicelloUniversity of Torino, Orbassano, Italy.
Emanuele FranchinUniversity of Torino, Orbassano, Italy.
Marinella ClericoUniversity of Torino, Orbassano, Italy.
Ospedale San Luigi Gonzaga · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive multifocal leukoencephalopathy (PML) is a serious infective disease of the central nervous system that may occur in case of severe immunosuppression or after some treatment for multiple sclerosis (MS) with natalizumab, dimethyl fumarate, and fingolimod. In these case reports, we highlight the importance of differential diagnosis between PML and MS lesions in order to provide rapidly the best treatment option, by discussing the finding of brain (magnetic resonance imaging) MRI suggestive for PML in 2 MS patients, one treated with dimethyl fumarate and the other during natalizumab withdrawal. In both cases, although brain MRI was highly suggestive for PML, the detection of John Cunningham virus-DNA copies in cerebrospinal fluid resulted in negative result. These case reports illustrate the diagnostic process in case of suspected PML, as both patients were diagnosed with suspected PML during a routine brain MRI control, and highlights the importance of providing a strict brain MRI follow-up during dimethyl fumarate treatment, although only a few cases of PML during this therapy have been detected, and during natalizumab suspension phase. In clinical practice, in case of a radiologically suspected case of PML, although not confirmed by the cerebrospinal fluid analysis, the best approach could be to perform a close radiological and clinical monitoring before starting a new MS therapy.

Indexed as

Cerebrospinal FluidDiagnosis, DifferentialDimethyl FumarateDNA, ViralFemaleFingolimod HydrochlorideHumansImmunologic FactorsJC VirusLeukoencephalopathy, Progressive MultifocalMagnetic Resonance ImagingMiddle AgedMultiple SclerosisNatalizumabPolymerase Chain ReactionViral LoadDimethyl FumarateDNA, ViralFingolimod HydrochlorideImmunologic FactorsNatalizumabbrain MRIdifferential diagnosisdimethyl-fumaratemultiple sclerosisnatalizumabprogressive multifocal leukoencephalopathy

Identifiers

PMID32646245
PMCPMC7357099
OpenAlexW3041573476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.